Rigel is a South San Francisco biotechnology company that develops and sells medicines for blood disorders and cancer. RIGL reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | HC Wainwright & Co. | Target lowered | Buy | |
| Aug 17 | Piper Sandler | Maintained | Hold | |
| Aug 14 | HC Wainwright & Co. | Target raised | Buy | |
| May 22 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How RIGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in RIGL in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RIGL is in one of them and how their past RIGL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RIGL in an article yet. Here's the latest on the wider market.
About Rigel Pharmaceuticals
Rigel is a biotechnology company based in South San Francisco, California, that develops and sells medicines for patients with blood disorders and cancer. Its approved products include TAVALISSE, an oral medicine for adults with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia, and GAVRETO for certain lung and thyroid cancers. The company is also developing other treatments, including an experimental drug for a blood disorder called myelodysplastic syndrome.
- Headquarters
- South San Francisco, CA